Harm-Benefit Analysis: opportunities for enhancing ethical review in animal research
To the Editor -The UK's Animals in Science Committee (ASC) recently completed its review of the processes of harm-benefit analysis (HBA) carried out under the UK Animals (Scientific Procedures) Act 1986 (ASPA) (see Supplementary material). The ASC report focuses on the UK, where ASPA requires the HBA of a programme of work to assess whether the harm that would be caused to protected animals, in terms of suffering, pain, distress, and lasting harm, can be justified by the expected outcome, taking into account ethical considerations and the expected benefit to human beings, animals, or the environment. ASPA additionally demands consideration of "important animal welfare or ethical concerns, novel or contentious issues, or societal concerns" 1 . Given these complex requirements, processes of HBA need regular review to operate in a way that is responsive to scientific and societal developments.
The 2017 ASC report concludes that HBA remains a legitimate ethical framework for evaluating the use of animals in research and makes 27 recommendations for improving the HBA (Supplementary material). This report thus contributes to evolving processes for the development of HBA 2, 3 . Some ASC report recommendations are targeted to the regulation of animal research in the UK, but the principles underpinning this report have relevance for other processes of HBA.
The long history and recent growth of HBA processes demonstrate that this ethical framework is both durable and flexible. However, as the ASC report outlines, HBA represents an ethical dilemma that cannot be fully resolved. Furthermore, the report suggests that the processes of HBA are not only important when making a prospective evaluation of the likely harms and potential benefits; they should also be applied to reduce harms and maximise benefits throughout the life of a project and to inform retrospective review. This report thus builds on the shift from understanding HBA as a one-off assessment to an openended and iterative process, which requires ongoing communication to help deliver robust and effective ethical review.
Debating harm-benefit analysis
Harm-benefit analysis has recently come under scrutiny from several different perspectives, raising questions about the nature of this ethical framework. In theory, HBA is a form of decisionmaking that uses moral reasoning based on utilitarianism and aims to maximize the balance of benefits over harms for all affected. In practice, HBA often operates within a wider set of interlocking social, ethical, and regulatory frameworks. In the UK, under ASPA, there are limits to experimentation on animals, which involves the recognition of some intrinsic animal rights. HBA is also implemented in a regulatory context that considers the importance of a culture of care, requires diligence from everyone involved to operate effectively, and engages a range of wider societal concerns. This relationship between different ethical frameworks may be one reason that HBA has proved enduring and adaptable over time. However, it also gives rise to complexities and ambiguities, as different kinds of ethical reasoning and societal concerns are mobilized for making judgements and shaping expectations about whether licences should be approved.
Some critiques of HBA have focused on the internal characteristics of this ethical decision, arguing that decisions should be further quantified, or that review processes be made more systematic 7 . Other critiques focus on the wider contexts to HBA, asking questions around transparency and inclusion: "for whom, for what, and by whom should a cost-benefit calculation be made?" 8 . There are, thus, different expectations about what HBA should look like as an ethical framework. Those who expect an objective scientific justification seek precise figures for aggregate harms and overall benefits, which can be used to calculate the outcome. Those who have been critical of the capacity of numbers to capture the different stakes around animal research will have different questions: which elements are being counted, whose perspectives are being included, and how are different views being weighed?
The ASC report outlines that an effective HBA should be a systematic process, based on best available data on the harms experienced by individual animals and specific project-related benefits, but also that each decision should be recognised as partial and provisional. This partiality reflects the different opinions and expectations of those who have a role in influencing, regulating, and implementing HBAs, whether as scientific researchers, animal technologists, veterinarians, ethical review bodies, research funders, regulators, or as lay committee members. The provisional nature of each HBA signals the ongoing changes in the recognition of the causes of animal suffering and developments in the assessment of benefits. Judgements are likely to change as new knowledge about animal behaviour and welfare becomes available, and as new ways of thinking and working evolve.
Opening-up harm-benefit analysis
The intention of the ASC report is to open up these processes of appraisal and to identify opportunities to deliver an ongoing and dynamic HBA, which is responsive to the developments across regulatory, scientific, societal, and animal welfare domains. The report seeks to move beyond debates over the pros and cons of HBA in principle, to see how existing processes of HBA can integrate new data on the assessment of harms and benefits and be informed by the emerging opportunities from retrospective review. The report asserts that improvements to ethical review will be supported by using the inevitable uncertainties involved in HBA as prompts to generate further data on harms and benefits and widen discussion of their relative importance.
The first part of this opening up is recognizing that interpretations of harms and benefits are not fixed in time. There are novel scientific frameworks to recognise and mitigate harms, especially around cumulative severity and the assessment of 'severe severity' , which are explored in detail in the report. There are new mechanisms for evaluating research design and research impact, which can be used to assess and improve the likelihood of benefits. The report also suggests that there are more opportunities for making explicit the criteria used to identify 'societal concerns' , Lab animaL | VOL 47 | MARCH 2018 | 57-58 | www.nature.com/laban 'ethical concerns' and 'novel or contentious issues' within and across processes of HBA. These are currently identified through isolated expressions of personal concern, stakeholder engagement, and horizon scanning. Different interpretations of harms, benefits, and societal concerns emerge through the range of local and national processes of ethical review and there is scope to connect these more systematically.
The second part of this opening up is recognising that processes of HBA are important throughout the life of a project. HBA has been primarily thought of as a prospective evaluation of the likely harms to animals and potential benefits of a program of research. However, the HBA, and any uncertainties in the initial HBA, can be used to direct efforts to reduce harms and maximize benefits throughout the research project. An ongoing HBA can also help recognise at what point a project, procedure, animal model, or research trajectory can no longer be ethically or scientifically justified. One frequent criticism of HBA as an ethical framework is the low number of projects which 'fail' to achieve a positive HBA at the project evaluation stage and at interim and retrospective reviews. Understanding HBA as an iterative process may better reflect the way projects are currently revised, with harms reduced and benefits optimised, before they are submitted to the regulator. However, it also raises the significance of processes of interim and retrospective review, when further data on animal suffering and potential benefits may be available.
The third element of opening up is around the level of harm above which licences should not be approved. The Minister commissioning the ASC review specifically requested advice on this point. The report has considerable detail on the definition, measurement, and scrutiny of 'severe' procedures, including a discussion of whether cumulative severity effects could increase severity to unacceptable levels. However, the ASC does not specify a level of harm above which licences should not be granted. The UK has seen issues move from receiving additional scrutiny in ethical review to subsequent exclusion through the application of HBA (for example, the use of great apes, testing cosmetics and household products and ingredients on animals). Weighing harms and benefits will always require people to make judgements informed by current science and societal concerns. However, there are additional opportunities for transparency, dialogue, and learning to enhance this aspect of HBA processes in the future.
improving harm-benefit analysis
The ASC report used academic and policy reviews, interviews, analysis of benefits, and committee discussion to make 27 recommendations to improve processes of HBA in the UK and elsewhere. These start with recommendations around the assessment of harm. Understandably, most work has been done on the harms experienced by animals, but there are still knowledge gaps. Further research to generate, evaluate, and critically integrate data on the level and nature of acute and chronic harms to animals will strengthen evidence around harms for HBA. The specific recommendations on harms focus on using the best available data on harms experienced by individual animals, collecting and sharing new data on cumulative severity, ensuring robust scientific and institutional challenges to severe procedures, and reviewing procedures based on the retrospective reviews (and assessments) and the actual severity data now collected in the EU. Connecting data across species, institutions, and over the course of a project should enable future HBA to be based on the best scientific evidence on the harms relevant to that species and developmental stage (and strain, where relevant) and experienced over the lifetime of the animal.
Direct research on the evaluation and optimisation of benefits from animal research has been more limited, but new forms of data on research benefits are now available. These are emerging from international agendas around translational biomedical research, demands from research funders and government for accountability, and attention from learned societies and others to research reliability, reproducibility, and integrity 9 . The ASC report seeks to integrate the insights from these debates. Specific recommendations around benefits focus on improving the uptake of good practice around systematic review, experimental design, research reporting, and ensuring researchers use appropriate methods to provide access to all research data, whether or not they support the original hypothesis. The recommendations are organized around the research stage and the different pathways taken by basic, translational, and regulatory research. This emphasis on benefits within the HBA is a novel contribution, with recommendations to ensure research benefits are not only detailed at the outset, but are also subject to ongoing review and improvement.
In many ways, the ASC report is making explicit the complexity of the way HBA operates as an ethical framework. As such, this report is not going to satisfy those who want to return a quantified outcome for the HBA. However, the ASC suggests that opening processes of HBA up to better data and better connections between data has the potential to improve their effectiveness and transparency. New data and new discussions will never remove the complexity of ethical evaluations in animal research. As Mark Walport suggests in his 2016 Paget Lecture its "complexity means that animal research is a topic where the institutions of science meet the institutions of democracy fairly and squarely. It is an area where the arguments will continue and the opposing cases will need to be made and remade" 10 . The debates around HBA are an important opportunity for these arguments to be made and remade and through which opportunities for learning and discussion across different perspectives can be enhanced. ❐
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